Market capitalization | €13.41b |
Enterprise Value | €24.41b |
P/E (TTM) P/E ratio | 20.35 |
EV/FCF (TTM) EV/FCF | 15.60 |
EV/Sales (TTM) EV/Sales | 1.27 |
P/S ratio (TTM) P/S ratio | 0.70 |
P/B ratio (TTM) P/B ratio | 0.98 |
Dividend yield | 2.60% |
Last dividend (FY23) | €1.19 |
As a Free StocksGuide user, you can view scores for all 6,879 stocks worldwide.
22 Analysts have issued a Fresenius Medical Care forecast:
22 Analysts have issued a Fresenius Medical Care forecast:
Sep '24 |
+/-
%
|
||
Revenue | 19,239 19,239 |
1%
1%
|
|
Gross Profit | 4,836 4,836 |
2%
2%
|
|
EBITDA | 3,180 3,180 |
2%
2%
|
EBIT (Operating Income) EBIT | 1,634 1,634 |
9%
9%
|
Net Profit | 659 659 |
46%
46%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
Head office | Germany |
CEO | Helen Giza |
Employees | 119,845 |
Founded | 1996 |
Website | www.freseniusmedicalcare.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.